National Accounts Director responsible for start-up of Biocon Pharma business development with State and Duel State Licensing and all phases of distribution for U.S. and Puerto Rico for Biocon Pharma private label ANDA product portfolio pipeline. Responsible for Biocon's US and PR distribution operations in accordance with approved sales-marketing plans directed at top national and regional wholesale, retail, GPO accounts identifying new market opportunities to attain or exceed an assigned quarterly/annual profit plan objectives with expertise in 24+ combined product launches in US for Rx Brand, Generic, OTC and 510k Medical Devices.

Key responsibilities: Managing day to day trade relations to maintain US wholesale and retail sales distribution supply channel inventories including all trade communications for Rx brand and generic business. Responsible for all phases of US pre/post operations for new product launches and/or product acquisition label transfers including all communications to trade partners and compendium data suppliers. Duties also include all product discontinuation phase-out operations with results inventory management to maximize retail pull-through while bleeding down wholesale channel inventories to minimize returns.

As InVentiv Health Director National Accounts for Aton Pharma, Inc., my direct responsibilities managed all phases of Aton’s new product label transfer from Merck & Co. and launch to U.S. wholesale, retail, through DDN 3PL supply channel distribution activities. Duties included all product communications to compendia data suppliers and trade supply partners from Aton Pharma, Inc., start-up in 2006 to Aton’s 2010 acquisition by Valeant Pharmaceuticals for approximately $318 million. Aton Pharma’s product transfer/launch responsibilities: Mephyton, Edecrin, Edecrin Sodium, Cuprimine, Syprine, Demser, and Lodsyn for global orphan product diseases; and Lacrisert, Timoptic, Timoptic-XE, and Timoptic in Ocudose for ophthalmic diseases.

1998 -1999 – National Flu-Vaccine Sales Manager: Responsible for managing sales for all 30 million single flu doses manufactured by King Pharmaceutical’s (Parkedale Pharmaceuticals) Sterile Products Operations facility during the 1999 U.S. influenza season through partnering with two US national physician office medical disposable/injectable distributors Besse Medical Inc. and PSS -Physician Sales & Service- selling though King’s inventories competing with Connaught/Aventis Pasteur and Wyeth. 2000 – 2004 Director of Corporate Accounts: Responsible for negotiating King’s Levoxyl IMA contract with Walgreens while competing with national leader Abbott Labs Synthroid. Walgreens market share helped King Pharm to maintain 35% of the U.S. levothyroxine market with Abbot Labs Synthroid 60% and Unithroid 5%.

Steris Labs National Accounts Manager - Sold sterile injectable product line to physician and veterinary distributors in Midwest and Northeastern US. Based out of Cincinnati, OH. Later included Schein Pharmaceutical's list of generic products to US distributors.Parks Medical Supplies Nashville, TN 07/1987 – 08/1990 Purchasing and Marketing Manager – Purchased and marketing manager for injectable product line to physicians for 12 Tennessee reps.Boots Pharmaceuticals 6540 Line Ave. Shreveport, LA (HQ Nottingham, UK) 03/1980 – 06/1987 Pharmaceutical Sales Rep – Sold Rx brand strength product Rufen (Motrin-ibuprofen) and sterile injectable product line to physicians in Dallas for two years before re-locating to South Texas territory based in Corpus Christi covering Victoria, Port Aransas, South Padre Island to Rio Grande Valley; Brownsville, Harlingen, McAllen and Laredo.